Title for MeetingAbstracts
Alphabetical listing of titles
Protease inhibitors are associated with favorable response to topical treatment of Kaposi's sarcoma.
Protease inhibitors are associated with less neuropsychological impairment in HIV infection.
Protease inhibitors based regimens and neuropsychological performance in HIV-1 patients. Neuroscience of HIV Infection.
Protease inhibitors containing regimens: the reasons of absence of initial virological response.
Protease inhibitors decrease CD4+ T cell apoptosis in HIV-infected patients.
Protease inhibitors in children under 12 years of age--the Australian experience.
Protease inhibitors in children with HIV-infection.
Protease inhibitors lead to a change of infectious diseases unit activity.
Protease Inhibitors May Increase Risk of Cardiovascular Disease in HIV-infected Patients.
Protease Inhibitors Reduce Apoptosis through a Mechanism which Is Independent of Caspase Inhibition.
Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation.
Protease inhibitors.
Protease inhibitors: experiences of women with HIV/AIDS.
Protease inhibitors: use and effects in an HIV clinic.
Protease inhibitors: use and effects in an HIV clinic.
Protease Sequences from HIV-2 Subtypes A and B Harbor Multiple Mutations Associated with Protease Inhibitor Resistance in HIV-1.
Protease Sparing Regimen in a Real Life Practice with Naive Patients: An Equal Opportunity Approach?
Protease-defective gp120-containing HIV-1 particles induce apoptosis more efficiently than wild-type virus in mitogen-stimulated healthy donor-derived peripheral blood cells.
Protease-defective HIV particles produced from long-term surviving HIV-infected MT-4 subclones are highly efficient in causing syncytia or apoptosis of uninfected human hematopoietic cell lines.
Protease-inhibitor regimen associated with hypercholesterolemia in an urban pediatric clinic.
PROTEASOME AND GLUCOSE TRANSPORT INHIBITION: A UNIFYING HYPOTHESIS FOR THE MECHANISM OF PROTEASE INHIBITOR INDUCED METABOLIC DISTURBANCES AND FOR THE SUPERIOR LIPID PROFILE OF ATAZANAVIR (ATV).
PROTEASOME INHIBITION INTERFERES WITH GAG POLYPROTEIN PROCESSING, RELEASE AND MATURATION OF HUMAN IMMUNODEFICIENCY VIRUSES.
PROTEASOME INHIBITORS INTERFERE WITH RELEASE AND MATURATION OF RETROVIRUSES: POTENTIAL MECHANISM(S) AND THERAPEUTIC APPLICATION.
Protecting and promoting human rights.
Protecting confidentiality in a national reporting system for HIV services.
Protecting paradise: tourism and AIDS in the Dominican Republic.
Protecting school girls against sexual exploitation: development of a guardian programme in Tanzania.
Protecting the partner: Sexual behaviours of partners who are HIV positive in discordant relationships, in rural KwaZulu-Natal, South Africa.
Protecting traditional healer (TH) intellectual property: in relation to HIV/AIDS prevention and management.
Protecting vulnerable populations in Medicaid managed care: Maryland's systems approach.